Fingerprint
Dive into the research topics of 'Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
Iftekhar Khan*, Stephen Morris, Allan Hackshaw, Siow Ming Lee
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
15
Citations
(Scopus)